PEAK PROCESSING LIMITED — Regulatory Filings 2019

Jun 20, 2019

==> picture [122 x 80] intentionally omitted <==

==> picture [136 x 82] intentionally omitted <==

ASX Announcement | 21 June 2019 Althea Group Holdings (ASX:AGH)

Althea Receives First Prescription in UK; Cultivation and Manufacturing Facility Planning Permit Granted

Investment Highlights:

• Althea receives its first patient prescription for medicinal cannabis in the UK

• Planning permit granted for Althea’s Cultivation and Manufacturing facility

21 June 2019: Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) (‘Althea’ or ‘the Company’) is pleased to announce its wholly owned subsidiary, Althea MMJ UK Ltd, has received its first patient prescription in the United Kingdom (UK) for Althea medicinal cannabis. Further to this key milestone, a planning permit has been issued by Frankston City Council for Althea’s Australian cultivation and manufacturing facility.

The receipt of the first prescription in the UK is the result of many months work, since Althea’s February 2019 announcement that it had entered the highly regulated UK market. The Company expects to receive more patient prescriptions in the coming days and will export Althea products from Australia, in order to satisfy demand.

Althea CEO Josh Fegan said: “We are excited to have received our first prescription for Althea medicinal cannabis in the UK. We are familiar with the significance of achieving a first prescription from our experience in Australia, where Althea recently surpassed the 1,000-patient milestone. The preparation and work which has resulted in our first prescription cannot be underestimated. From small things, big things grow.”

The UK will create a second significant distribution channel for Althea’s current and future Australian manufactured, medicinal cannabis products.

The UK announcement comes at the same time the planning permit was granted for Althea’s fully funded Victorian-based, Office of Drug Control (ODC) approved, cultivation and manufacturing facility. The permit is the culmination of a process which involved both the Victorian State Government and Frankston City Council and represents significant progress for the project.

Althea Director of Cultivation Daniel Mansfield said: “The Althea production team is excited following the granting of the planning permit for the Skye manufacturing and cultivation facility. It has been an absolute pleasure working closely with Aphria, Inc on the design of this world-class facility, along with many Australian based consultants. We will continue to work toward our goal of meeting a 2020 production target, as we progress to the next goal of obtaining our building permit.”

The granting of the planning permit and receipt of its first prescription in the UK follows Althea’s recent 1,000 patient milestone in Australia announcement, adding to the company’s growth momentum.

Mr Fegan added: “Althea is very pleased to be able to provide an update regarding our fully funded, ODC approved cultivation and manufacturing facility. I would like to

Althea Group Holdings Limited (ASX:AGH)  www.althea.life ACN 626 966 943  Level 37, 360 Elizabeth Street, Melbourne 3000

1

==> picture [122 x 80] intentionally omitted <==

thank the Victorian Government, and in particular Invest Victoria, as well as the Frankston City Council. Operating within such a highly regulated industry requires constant interaction with all levels of government and this permit represents the success of industry working with government.”

Ends

For further information, please contact:

Althea

Media Enquiries

Josh Fegan

Julia Maguire M: +61 419 815 386

CEO & Managing Director The Capital Network M: 1300 70 20 20 M: +61 419 815 386

E: contact@althea.life E: julia@thecapitalnetwork.com.au

Australian Investors

PAC Partners Securities

M: 03 8633 9834

E: enquiries@pacpartners.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life

Althea Group Holdings Limited (ASX:AGH)  www.althea.life ACN 626 966 943  Level 37, 360 Elizabeth Street, Melbourne 3000

2